Evaluation and Predictive Value of Genetic Polymorphisms in the Management of Hormonal Treatment of Prostate Cancer

UnknownOBSERVATIONAL
Enrollment

250

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions
Prostate Cancer
Interventions
GENETIC

Saliva sample collection for genetic analyses

Patients with Prostate cancer receiving androgen deprivation treatment with a GnRH antagonist will be followed-up for 6 months for quality of life. At Baseline, 3 months and 6 months of treatment QoL data will be collected, as well as body parameters. At Baseline, once, a saliva sample will be collected for genetic analyses.

Trial Locations (20)

1000

RECRUITING

CHu Saint Pierre, Brussels

1070

RECRUITING

Hopital Erasme, Brussels

1200

RECRUITING

Cliniques Universitaires Saint Luc, Brussels

1800

RECRUITING

AZ Jan Portaels, Vilvoorde

2020

RECRUITING

ZNA Middelheim, Antwerp

2170

RECRUITING

ZNA Jan Palfijn, Merksem

2300

RECRUITING

AZ St Jozef, Turnhout

2390

WITHDRAWN

AZ Sint Jozef, Malle

3500

RECRUITING

JESSA Ziekenhuis, Hasselt

4000

RECRUITING

CHR Citadelle, Liège

5004

RECRUITING

Clinique Saint Luc Bouge, Namur

5530

RECRUITING

CHU Mont-Godinne, Yvoir

7100

RECRUITING

CHU Tivoli, La Louvière

7700

RECRUITING

CH Mouscron, Mouscron

8400

RECRUITING

AZ Damiaan, Ostend

8800

RECRUITING

AZ Delta, Roeselare

8900

WITHDRAWN

Jan Ypermanziekenhuis, Ieper

9200

RECRUITING

AZ Sint Blasius, Dendermonde

9300

RECRUITING

ASZ Aalst, Aalst

RECRUITING

OLV Aalst, Aalst

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ferring Pharmaceuticals

INDUSTRY

lead

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

OTHER